Tissue Regeneration and Inflammation Imaging
This group aims at developing and validating molecular imaging techniques to study, particularly, inflammatory and extracellular matrix-modifying processes. Our research consists of three lines. Firstly, we focus on the development and validation of targeted compounds for detection of early biomarkers of pathology using PET, SPECT, optical imaging or MRI. Secondly, selected substances are tested for their suitability as therapeutic agents. Specific examples of such compounds are selective cyclooxygenase-2 inhibitors for diagnostic targeting and therapeutic modulation of inflammatory processes, particularly, associated with biomaterial approaches for bone and soft tissue regeneration as well as with solid tumors. Selective transglutaminase-2 inhibitors address matrix-modifying processes in tissue regeneration or tumor progression. Thirdly, we study animal models for pathologies such as critical bone defects as well as selected tumors with a pronounced pro-inflammatory and matrix-associated microenvironment to improve our understanding of the disease process.
- Xu Y et al., Adv. Sci., 2019, 6:180277.
- Hauser S et al., Trends Biotechnol. 35:265-277, 2017.
- Tondera C et al., Theranostics 6:2114-2128, 2016.
- Tondera C et al., Adv. Funct. Mater. 27: 1605189, 2017.
- Functional Biomaterials for Controlling Healing Processes in Bone and Skin - From Material Science to Clinical Application; DFG, Transregio Collaborative Research Centre TRR67; subproject B5.
- MATRESIST: Matrix-Associated Therapy Resistance
Further literature on our hypotheses (ref. critical-size bone defects: review series Part I; Part II; Part III; comment; ref. biocompatibility: ; ref. inflammation imaging: ; ref. bone healing imaging: )